PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32870322-6	2020	We further found that metformin significantly suppressed NLRP3 inflammasome activation, subsequent caspase-1 cleavage, and interleukin-1beta secretion in both peripheral macrophages and central hippocampus.	Metformin	22-31	interleukin 1 beta	Mus musculus	123-140	
31945013-8	2020	METHODS: The effects of metformin on cartilage degradation and chondrocyte aging was determined in a destabilization of the medial meniscus (DMM)-induced OA mouse model and in IL-1beta-treated mouse chondrocytes and cartilage explants.	Metformin	24-33	interleukin 1 beta	Mus musculus	176-184	
31195189-6	2019	Metformin prevented atrophy of myelinated axons, and reduced expression of inflammatory mediators (interleukin-1beta, inducible nitric oxide synthase and nitric oxide).	Metformin	0-9	interleukin 1 beta	Mus musculus	99-116	
31319131-6	2019	We found that the metformin pretreatment alleviated the lung injury and decreased the levels of TNF-a, IL-1beta and IL-6 in the bronchoalveolar lavage fluid (BALF) and in lung tissues, as well as the levels of NLRP3, NLRC4 and cleaved caspase-1 associated with LPS-induced ALI in old mice.	Metformin	18-27	interleukin 1 beta	Mus musculus	103-111	
30935688-7	2019	The current results showed that metformin activated autophagy and decreased the mRNA expressions of inflammatory cytokines, IL-1beta, IL-6, and TNF-alpha via inhibition of the STAT3 mRNA and protein expression.	Metformin	32-41	interleukin 1 beta	Mus musculus	124-132	
30945296-9	2019	RESULTS: We found that metformin treatment can robustly ameliorate periodontal infection and tissue destruction and reduce blood glucose and serum IL-1beta levels in mice with diabetic periodontitis.	Metformin	23-32	interleukin 1 beta	Mus musculus	147-155	
29655055-3	2018	The levels of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha were decreased by GE, metformin and fasudil in diabetic db/db mice.	Metformin	129-138	interleukin 1 beta	Mus musculus	45-67	
30584213-3	2019	In this study, we investigated the inhibitory property of metformin on mitochondrial damage by focusing on the interleukin-1 beta (IL-1beta)-stimulated osteoarthritis model by using primary murine chondrocytes.	Metformin	58-67	interleukin 1 beta	Mus musculus	111-129	
30584213-3	2019	In this study, we investigated the inhibitory property of metformin on mitochondrial damage by focusing on the interleukin-1 beta (IL-1beta)-stimulated osteoarthritis model by using primary murine chondrocytes.	Metformin	58-67	interleukin 1 beta	Mus musculus	131-139	
30779140-10	2019	RESULTS: We found that metformin treatment can robustly ameliorate periodontal infection and tissue destruction and reduce blood glucose and serum IL-1beta levels in mice with diabetic periodontitis.	Metformin	23-32	interleukin 1 beta	Mus musculus	147-155	
28018360-7	2016	Importantly, metformin administration increased the mortality of mice with bacterial sepsis, which was likely because metformin treatment enhanced the systemic inflammasome activation as indicated by elevated serum and hepatic IL-1beta levels.	Metformin	13-22	interleukin 1 beta	Mus musculus	227-235	
28559290-7	2017	Treatment of adipocytes with metformin decreased the effects of lipopolysaccharide on inducing the phosphorylation states of JNK p46 and on increasing the mRNA levels of IL-1beta and TNFalpha.	Metformin	29-38	interleukin 1 beta	Mus musculus	170-178	
29157127-5	2018	Metformin treatment decreased the expression of IL-1beta and IL-6 in epididymal fat, which was correlated with the abundance of various bacterial genera.	Metformin	0-9	interleukin 1 beta	Mus musculus	48-56	
29554661-6	2018	RESULTS: The contents of pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor (TNF)-alpha were inhibited by ALK, metformin or fasudil in diabetic db/db mice.	Metformin	143-152	interleukin 1 beta	Mus musculus	52-74	
28410530-3	2017	In the present study, we found that treatment with metformin inhibited the cardiac expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) in endotoxin-challenged mice.	Metformin	51-60	interleukin 1 beta	Mus musculus	175-193	
28410530-3	2017	In the present study, we found that treatment with metformin inhibited the cardiac expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) in endotoxin-challenged mice.	Metformin	51-60	interleukin 1 beta	Mus musculus	195-203	
28439456-14	2017	ELISA assay revealed decreased levels of inflammatory response marker IL-1beta and TNF-alpha in the pancreatic tissues following metformin treatment.	Metformin	129-138	interleukin 1 beta	Mus musculus	70-78	
27733575-7	2017	Furthermore, we show that a culture of AECs with either fenoldopam or the AMPK activator metformin effectively diminished IL-1beta-induced release of adverse paracrine signaling, which promotes the macrophage proinflammatory response.	Metformin	89-98	interleukin 1 beta	Mus musculus	122-130	
28002460-9	2016	In addition, metformin supplementation in IL10KO mice suppressed macrophage pro-inflammatory activity as indicated by reduced M1 macrophage abundance and decreased pro-inflammatory cytokine IL-1beta, TNF-alpha and IFN-gamma expressions.	Metformin	13-22	interleukin 1 beta	Mus musculus	190-198	
28018360-7	2016	Importantly, metformin administration increased the mortality of mice with bacterial sepsis, which was likely because metformin treatment enhanced the systemic inflammasome activation as indicated by elevated serum and hepatic IL-1beta levels.	Metformin	118-127	interleukin 1 beta	Mus musculus	227-235	
26303871-5	2015	The leucine-metformin combinations reduced fat pad mass, normalized liver weight, liver and plasma lipids and inflammatory markers (interleukin 6, interleukin 1 beta, tumor necrosis factor alpha, monocyte chemotactic protein-1, C-reactive protein) comparable to the effects of therapeutic metformin.	Metformin	12-21	interleukin 1 beta	Mus musculus	147-194	
25315906-11	2014	In addition, metformin activated AMPK phosphorylation, inhibited NF-kappaB activation, down-regulated cytokine (IL-1beta, IL-6, TNF-alpha) and ICAM-1 expression following tMCAO (P < 0.05).	Metformin	13-22	interleukin 1 beta	Mus musculus	112-120	
24009539-5	2013	Metformin reduced the production of NO, PGE2 and pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) through down-regulation of NF-kappaB translocation in macrophages in a dose-dependent manner.	Metformin	0-9	interleukin 1 beta	Mus musculus	77-85	
21091653-6	2011	KEY RESULTS: Both pre- and post-treatment with metformin significantly improved survival of animals during lethal endotoxaemia (survival rate was monitored up to 2 weeks), decreased serum levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta, HMGB1 expression and myeloperoxidase activity in lungs.	Metformin	47-56	interleukin 1 beta	Mus musculus	240-257